Product Description
TLR9 Agonist for Myeloid Malignancies and Lymphoid Malignancies (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02452697)
Mechanisms of Action: TLR9 Agonist
Novel Mechanism: Yes
Modality: Large Molecule
Route of Administration: Intravenous, Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Cristina Gasparetto
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Pregnancy Outcomes|Bone Marrow Transplantation|Environmental Hypersensitivity|Graft vs Host Disease|Animal Hypersensitivity|Nut Hypersensitivity|Liver Transplant|Hematopoietic Stem Cell Transplant|Allogeneic Stem Cell Transplant|Lymphoma, Non-Hodgkin
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02452697 |
NK-DCI | P2 |
Active, not recruiting |
Liver Transplant|Environmental Hypersensitivity|Bone Marrow Transplantation|Pregnancy Outcomes|Graft vs Host Disease|Hematopoietic Stem Cell Transplant|Allogeneic Stem Cell Transplant|Nut Hypersensitivity|Animal Hypersensitivity |
2022-07-23 |
50% |
2024-02-21 |
Patient Enrollment|Primary Endpoints|Treatments |
NCT02115126 |
Pro00042574 | P2 |
Withdrawn |
Lymphoma, Non-Hodgkin |
2020-01-01 |
2019-03-20 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|